Abstract
One of the challenges faced by neurologists seeing patients with neuromuscular disease is distinguishing one form of immune-mediated neuropathy from another.1–3 This is more than an academic question because diagnosing a patient with Guillain-Barre syndrome vs acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has implications for treatment as well as prognosis. For example, are corticosteroids, arguably the most readily available and least costly therapy for chronic immune neuropathy, indicated or not? Consensus panels of experts often produce diagnostic criteria by mutual agreement, developing guidelines based on rigorous scientific evidence that may provide superior tools for accurate diagnosis and …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.